Full-Time

Microbiology Technician 3

Quality Control

Updated on 9/4/2026

Kincell Bio

Kincell Bio

51-200 employees

Cell therapy CDMO: development, CMC, manufacturing

No salary listed

Durham, NC, USA

In Person

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Microsoft Office
Inventory Management
GMP
Microbiology
Data Analysis

Get referred to Kincell Bio

See people who can refer or advise you

Requirements
  • A bachelor's degree in microbiology, biology, or another relevant scientific discipline with at least 2 years of relevant microbiology laboratory experience, or at least 5 years of relevant microbiology laboratory experience in lieu of a degree.
  • Demonstrated experience performing environmental monitoring in a classified cleanroom or controlled environment.
  • Hands-on experience with aseptic gowning and working within classified cleanroom environments.
  • Demonstrated experience performing microbiological testing in a GMP-regulated pharmaceutical, biotechnology, cell therapy, or similarly regulated environment.
  • Experience with applicable microbiological methods, including environmental monitoring, bioburden, bacterial endotoxin, microbial enumeration, growth promotion, Gram staining, subculture techniques, microbial identification, and sterility testing.
  • Experience with microbiological data analysis, trending, and technical report generation.
  • Demonstrated ability to work independently, exercise sound judgment, and complete assigned activities with minimal direct supervision.
  • Strong organizational, analytical, and problem-solving skills with the ability to prioritize and manage multiple activities or projects simultaneously.
  • Ability to define problems, collect and evaluate data, establish facts, identify trends, and draw scientifically sound conclusions.
  • Strong attention to detail and commitment to accuracy, compliance, and data integrity.
  • Effective written and verbal communication skills, with the ability to communicate technical information clearly and professionally.
  • Demonstrated ability to adapt to a rapidly changing environment while maintaining quality, productivity, and compliance.
  • Proficiency with Microsoft Office applications and applicable laboratory information management systems.
  • Ability to work off-hours, weekends, or extended hours as required to support manufacturing and environmental monitoring activities.
  • Ability to wear required cleanroom and personal protective equipment, including full-body gowning, goggles, face shields, protective gloves, and other applicable personal protective equipment.
Responsibilities
  • Perform routine and non-routine environmental monitoring of classified cleanrooms and laboratory areas, including viable air, surface, personnel, compressed gas, and other applicable monitoring, in support of GMP manufacturing operations.
  • Perform environmental monitoring activities during off-hours, weekends, and other non-standard schedules as required to support manufacturing operations.
  • Serve as a senior technical resource for microbiology and environmental monitoring activities and provide guidance and support to other microbiology personnel as needed.
  • Perform critical utility microbiological monitoring in accordance with approved procedures, specifications, and established schedules.
  • Perform microbiological quality-control testing of raw materials, in-process materials, and other applicable samples in accordance with approved procedures and GMP requirements.
  • Perform microbiological assays including bioburden, bacterial endotoxin, microbial enumeration, Gram staining, microbial identification, subculture techniques, plate reading, and other applicable microbiological methods.
  • Perform sterility testing, method verification, method suitability, and other microbiological testing activities as qualified, including use of automated microbial detection systems such as the BacT/ALERT 3D System.
  • Prepare microbiological media, buffers, reagents, and other laboratory materials in accordance with approved procedures.
  • Perform growth promotion testing and qualification of microbiological media in accordance with approved procedures and applicable compendial requirements.
  • Coordinate microbiological testing with external contract laboratories, including sample submission, test requirements, scheduling, result review, and reconciliation of final reports.
  • Manage and coordinate contract laboratory testing for environmental monitoring and other microbiological analyses, as assigned.
  • Perform routine data review, analysis, and trending of microbiological and environmental monitoring data and contribute to technical reports and scientifically sound conclusions.
  • Initiate and support environmental monitoring and microbiological assay investigations, including assessment of atypical results, alert/action level excursions, out-of-specification results, and other microbiological events.
  • Assist with root cause investigations, impact assessments, corrective actions, and effectiveness evaluations associated with microbiological events.
  • Assist with qualification and validation of microbiology equipment, processes, facilities, and analytical methods, including protocol development, execution, data collection, and report generation.
  • Perform routine laboratory equipment maintenance, calibration activities, and troubleshooting as required.
  • Review laboratory data, worksheets, test records, and other controlled documentation for accuracy, completeness, and compliance with GMP and data integrity requirements.
  • Maintain the microbiology laboratory in a clean, organized, compliant, and inspection-ready condition.
  • Support laboratory readiness activities, including inventory management, preparation of laboratory supplies, and monitoring of media, reagents, and consumables.
  • Identify opportunities to improve microbiology laboratory processes, environmental monitoring practices, testing efficiency, and overall laboratory performance.
  • Train and provide technical guidance to less-experienced microbiology personnel on applicable laboratory procedures and microbiological techniques, as assigned.
  • Maintain proficiency in applicable microbiological methods and complete required training and competency assessments.
  • Comply with company policies, procedures, standard operating procedures, GMP requirements, applicable regulatory expectations, and data integrity principles.
Desired Qualifications
  • Experience with microbiology investigations, environmental monitoring excursions, atypical results, or out-of-specification events.
  • Experience supporting microbiology equipment, method, or process qualification and validation activities.

Kincell Bio provides manufacturing and development services for companies creating immune cell therapies, such as CAR-T and CAR-NK treatments. The company works by acting as an extension of its clients' teams, handling the complex process of turning laboratory research into clinical-grade products through specialized consulting and factory production. Unlike larger competitors, Kincell focuses specifically on the needs of early-stage biotech startups and academic spinouts by offering personalized partnerships and scalable facilities. Its goal is to streamline the path from initial research to clinical trials by solving the manufacturing challenges that often slow down new medical treatments.

Company Size

51-200

Company Stage

Early VC

Total Funding

$58M

Headquarters

Gainesville, Florida

Founded

2023

Get referred to Kincell Bio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • The 2026-04-14 RTP investment directly meets rising late-stage and commercial supply demand.
  • NewSpring's 2025-05-15 $22 million round extends runway for equipment, quality, and systems.
  • Kincell's Gainesville and RTP split supports early development, pivotal supply, and launch manufacturing.

What critics are saying

  • RTP expansion must finish by Q3 2026; any delay misses commercialization timelines.
  • Lonza, Catalent, and Forge Biologics outspend Kincell on capacity, quality systems, and client acquisition.
  • A single clinical-program concentration or client loss can cripple revenue before commercial scale arrives.

What makes Kincell Bio unique

  • Larry Pitcher became CEO on 2026-01-06 after scaling Catalent's Maryland gene therapy site.
  • Kincell's RTP expansion added two ISO 7 suites, targeting late-stage and commercial cell therapies.
  • The RegCell partnership on 2026-02-10 embeds Kincell in autoimmune Treg clinical manufacturing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

Stock Options

Company Equity

401(k) Retirement Plan

401(k) Company Match

Performance Bonus

Profit Sharing

Employee Stock Purchase Plan

Relocation Assistance

Employee Referral Bonus

Student Loan Assistance

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Pet Insurance

Bereavement Leave

Professional Development Budget

Conference Attendance Budget

Training Programs

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Wellness Program

Mental Health Support

Gym Membership

Commuter Benefits

Meal Benefits

Phone/Internet Stipend

Home Office Stipend

Legal Services

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

0%
European Pharmaceutical Review
Jan 19th, 2026
Kincell Bio promotes Bruce Thompson to President and Chief Technology Officer

Kincell Bio promotes Bruce Thompson to President and Chief Technology Officer. The cell therapy-focused CDMO has also elevated Melodie Bryce to Chief Quality Officer and Matt Haines to Chief Operations Officer. Cell therapy-focused contract development and manufacturing organisation (CDMO) Kincell Bio has made a trio of promotions to its senior leadership team. * Mandatory essentials of USP General Chapter 41 -calibration, minimum weight, repeatability and accuracy requirements, and performance checks * Informational statements of USP General Chapter 1251 - the concept of a safety factor * Performance checks - general requirements Its speaker will address specific USP-related questions in a Q&A format at the end of the webinar. The US firm has promoted its founding CEO Bruce Thompson to President and Chief Technology Officer and elevated Melodie Bryce to Chief Quality Officer and Matt Haines to Chief Operations Officer. Kincell Bio's Chief Executive Officer Larry Pitcher said: "Bruce, Melodie and Matt have demonstrated exceptional leadership and expertise, and their expanded roles further strengthen its ability to deliver innovative, high-quality solutions for its clients while accelerating access to transformative therapies for patients. "Together with our highly skilled teams, we will continue to expand our clinical development and commercial supply infrastructure, accelerate technology transfer and strengthen our commitment to delivering life-changing cell therapies efficiently and reliably." Thompson's prior leadership roles include VP of Process Sciences at Lyell Immunopharma. He has also held technical and operational leadership positions at Resilience and Fred Hutchinson Cancer Research Center, where he led GMP manufacturing of cell and gene therapy products. Bryce has nearly three decades of experience in quality leadership, spanning cell therapy, antibody and aseptic production, previously held senior quality leadership roles at KBI Biopharma, Cognate BioServices, Matica Biotechnology and Fujifilm Diosynth Biotechnologies. Meanwhile, Haines brings to his new role over 20 years of biotech experience, specialising in manufacturing sciences and operations at Biogen, Amgen and Merck. Before joining Kincell, he served as VP of Manufacturing Operations at Inceptor Bio, a cell therapy innovator, and Senior Director at AveXis/Novartis Gene Therapies.

Contract Pharma
Jan 6th, 2026
Kincell Bio Promotes Lawrence Pitcher to CEO

Kincell Bio promotes Lawrence Pitcher to CEO. Pitcher offers experience scaling cell and gene therapy manufacturing operations and aligning them with client and patient needs. Kincell Bio, a contract development and manufacturing organization (CDMO) in cell therapy, has promoted Lawrence "Larry" Pitcher to Chief Executive Officer, effective immediately. Pitcher succeeds Mark R. Bamforth OBE, who guided the company through a successful phase of growth as CEO and will continue to support the transition in a strategic capacity as Executive Chair of the Board. "Larry has a proven track record scaling cell and gene therapy manufacturing operations and aligning them with client and patient needs," said Mark R. Bamforth OBE. "His leadership of our operational capabilities positions Kincell Bio to better serve our clients as they progress into late-stage trials and commercial launch." As COO since March 2025, Pitcher has been instrumental in applying his experience to expanding Kincell Bio's production capabilities, processes, and systems to support pivotal and commercial-stage cell therapies. Prior to joining Kincell Bio, he served as VP & GM at Catalent's Maryland gene therapy site where he cultivated robust commercial manufacturing operations and drove significant revenue and profitability gains. His earlier roles include leadership positions at Thermo Fisher, Brammer Bio, and RTI Surgical across Europe and the U.S., where he delivered consistent operational excellence and growth. With a B.S. in Industrial Engineering from Western Michigan University and an MBA from the University of Florida, Pitcher brings technical expertise and strategic vision to the CEO role. He takes the helm at a pivotal time as Kincell Bio accelerates cell therapy product supply from its Research Triangle Park, NC, and Gainesville, FL sites. "I'm honored to assume the CEO role at Kincell Bio. Together with our skillful teams, we will expand our clinical development and commercial supply infrastructure, accelerate technology transfer, and strengthen our commitment to deliver life-changing cell therapies efficiently and reliably," Pitcher shared.

Business Wire
May 16th, 2025
NewSpring Capital and Kineticos Life Sciences Lead $22 Million Investment in Cell Therapy CDMO, Kincell Bio; Appoints Industry Veteran Pete Buzy to Board of Directors

Kincell Bio announced the completion of a $22 million round, led by a new investor, NewSpring Capital through its dedicated healthcare strategy, NewSpring He...

FinSMEs
May 15th, 2025
Kincell Bio Raises $22M in Funding

Kincell Bio raises $22M in funding.

Morningstar
May 15th, 2025
Kincell Bio secures $22M investment boost

NewSpring Capital and Kineticos Life Sciences led a $22 million investment in Kincell Bio, a cell therapy CDMO. Industry veteran Pete Buzy was appointed to Kincell Bio's Board of Directors. The funding will enhance Kincell Bio's cGMP capabilities and process development services. This positions Kincell Bio as a leader in biomanufacturing, with the cell and gene therapy market projected to surpass $23 billion globally by 2028.